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INTRODUCTION
Artemether ((3R, 5aS, 6R, 8aS, 9R, 10S, 12R, 12aR)-
decahydro-10-methoxy-3, 6, 9-trimethyl-3, 12-epoxy-
12Hpyrano [4,3-j]-1, 2-benzodioxepin) is a semisynthetic 
polyoxygenated amorphene-containing aperoxide bridge 
that confers potent antimalarial activity.[1] It is the O-methyl 
ether prodrug of dihydroartemisinin and a derivative of 
artemisinin (qinghaosu), the principal antimalarial constituent 
of the Chinese herb Artemisia annua (qing hao).[2] Artemether 
is active against the erythrocytic stage of multidrug-resistant 
strains of Plasmodium falciparum. The antimalarial activity has 
been attributed to chemical activation of the drug within the 
food vacuole of the intraerythrocytic stage of the parasite; 
it is proposed that reductive cleavage of the peroxide bridge 
by heme liberated during digestion of hemoglobin generates 
free radicals, which induce oxidative stress and alkylate heme 
and vital parasite proteins.[3] An interaction with membrane 
phospholipids has also been suggested.[4] The peroxide 
group in these compounds appears essential for activity 
and the peroxide group is retained in the active metabolite, 
dihydroartemisinin.[5]
Because of the promising activity exhibited by artemether 
against multidrug-resistant strains of P. falciparum, 
several researchers have focused on the development 
of various analytical methods to determine artemether 
in different matrices, such as plant extracts, serum, and 
pharmaceutical formulations. These methods include 
gas UV spectrophotometry,[5,6] high-performance liquid 
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chromatography (HPLC) based on UV absorption,[7-9] 
chromatography-mass spectrometry (GC-MS),[10] chemilu 
minescence and electrochemical detection,[11] high- 
performance thin-layer chromatography (HPTLC),[12,13] 
and the capillary electrophoresis techniques.[14] However, 
to the best of our knowledge no stability indicating HPLC 
method has been published in the available literature.
The aim of the present work is to develop and validate[15] 
an accurate, specific, and precise stability indicating HPLC 
method for determination of artemether as bulk drug and 
in solid dosage forms.
MATERIALS AND METHODS
HPLC Apparatus (shimadzu) equipped with LC-10 ATvp, 
double reciprocating plunger pump and SPD-10 Avp UV 
detector, and deuterium lamp as a light source ranging 
190-600 nm was used. Hypersil Octadecyl silane (ODS) 
column, (250 3 4) mm, 5 mm particle size of packing, 
pore size 120 A, Thermo Electron Corporation. Marketed 
formulations Larither and Falcidol capsules were purchased 
from a local market. Mobile phase selected was ACN 
and buffer in the ratio of 65:35 of pH 6.5 adjusted with 
tryethylamine. Wavelength selected was 210 nm. Standards 
and facilities were provided by Oasis Lab, Ahmedabad.
Preparation of a mobile phase
650 volumes of acetonitrile (ACN) was mixed with 0.005 M 
potassium dihydrogen phosphate (KH2PO4), adjusted to 
pH 6.5 with triethylamine filtered and degassed.
Preparation of 0.005 M KH2PO4
0.340 g KH2PO4 was transferred to a 500 ml volumetric 
flask and dissolved up to the mark with double distilled 
water.
Calibration curve
Suitable aliquots of the standard stock solution (10 mg/  ml) 
of ART (0.25, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65 and 0.75) 
were taken in 10 ml volumetric flasks and diluted with a 
mobile phase up to the mark to get 250, 350, 400, 450, 
500, 550, 600, 650, and 750 mg/ml solution of drug. The 
prepared solutions were then filtered through 0.45 m filter, 
and 20 ml of each solution was injected.
The calibration data, the linear regression equation, and 
correlation coefficient for artemether were found to be 
y 5 9355.5x 2 93.7 and r 5 0.9998, where y is response 
and x is the concentration of drug solution, respectively.
VALIDATION OF PROPOSED METHOD
Linearity
Linearity was assessed by two methods.
Visual examination
The numbers of points equally distributed on both sides 
of best fit line were inspected. From the calibration curve 
it is clearly seen that out of 9 points, 4 are on positive side 
(upper side of best fit line), 4 are on negative side (lower 
side of best fit line) and 1 is on the best fit line.
Residual analysis
Residuals were calculated and a graph was plotted between 
the residuals/deviations (predicted response-experimental 
response) and concentration. Distribution of residuals 
between upper and lower side of the regression line shows 
linearity.
Range
Working range
It begins from limit of quantification to the maximum 
concentration used for the development of the analytical 
method. In this case it is equal to 21.8317-750 mg/ml.
Linearity range
It is the interval in which the response is directly proportional 
to the concentration between the upper and lower levels 
(which is generally 65% of the intercept of average value). 
In this case it is equal to 250-750 mg/ml.
Target concentration
It is defined as the concentration which is equal to the 
midpoint of linearity range [(250 1 750)/2] 5 500 mg/ml.
Target range
It is that concentration which is 80%, 100% and 120% of 
the target concentration. In this case these are equal to 400, 
500, and 600 mg/ml.
Precision
Repeatability
Assessed by the area of six replicate determinations of 
ART solution at 100% of the target concentration, i.e. at 
500 mg/ml. RSD obtained because of variation in area was 
0.257 showing that the method it repeatable.
Intraday and Interday
Method was repeated at three concentration levels, i.e. 80%, 
100%, and 120% for three times in a day for intraday and in J Young Pharm Vol 2 / No 1  81
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three consecutive days for interday precision. RSD values 
obtained were 0.643 and 0.712 for intraday and interday, 
respectively.
Accuracy
5 ml of a preanalyzed capsule powder solution (500 mg/  ml) 
and 0.1, 0.2 and 0.3 ml of an ART standard solution 
(1 mg/  ml) were mixed within three different 10 ml 
volumetric flask, respectively. The estimation of drug was 
done by a proposed method. The results of recovery of 
Larither and Falcidol capsules are shown in Tables 1 and 2, 
respectively.
System suitability
Five injections of the same solution (500 mg/ml) were 
injected and variations between area and RT were observed. 
RSD due to changes in area and RT were found to be 0.274 
and 0.326, respectively. Asymmetric and tailing factors were 
1.20 and 1.30, respectively. The number of theoretical 
plates for the test concentration was 6998.
Limit of detection and limit of quantitation
The value of limit of detection (LOD) and limit of 
quantitation (LOQ) were calculated from the formula 
3.3 3 (SD/S) and 10 3 (SD/S), respectively, by using 
mean SD of data from the calibration curve. In this 
proposed method, 7.204 and 21.8317 mg/ml of ART are 
calculated as LOD and LOQ, respectively.
Estimation of artemether in a capsule dosage form
50 mg equivalent powder of a capsule dosage form was 
transferred to four different 50 ml volumetric flasks. 65 ml 
of ACN was added and sonicated for 15 min. The flasks 
were then diluted up to a volume with 0.005 M phosphate 
buffer, filtered with 0.45 mm filter, and 20 ml was injected.
A standard artemether solution was prepared by dissolving 
100 mg of drug in a 10 ml volumetric flask and diluting 
up to the volume. 0.5 ml of this solution was transferred 
to a 10 ml volumetric flask. Results of estimation of drug 
in two different capsule formulation are given in Table 3.
Table 1: Results of recovery of larither capsules
Conc. 
(mg/ml)
Conc. found before spiking 
(mg/ml) (C1)
Conc. of std added 
(mg/ml) (C2)
Conc. found after 
spiking (mg/ml) (C3)
%Recovery 
(C32C1)* 100/C2
Mean 6 S.D RSD
250 247.558 100 345.89 99.52 99.37 6 0.76 0.765
344.82 99.21
348.67 100.32
250 247.558 200 448.29 100.16
446.15 99.68
447.05 99.88
250 247.558 300 539.06 98.44
536.93 98.06
542.27 99.03
Table 2: Result of recovery study of falcidol caps
Conc. 
(mg/ml)
Conc. found before 
spiking (mg/ml) (C1)
Conc. of std added 
(mg/ml) (C2)
Conc. found after 
spiking (mg/ml) (C3)
%Recovery 
(C32C1)* 100/C2
Mean 6 S.D RSD
250 244.75 100 340.95 98.89 99.31 6 0.514 0.517
342.55 99.36
343.6 99.66
250 244.75 200 437.68 98.41
440.89 99.13
440.04 98.94
250 244.75 300 545.11 100.06
542.68 99.62
543.21 99.71
Table 3: Estimation of artemether in capsule dosage form
Brand name Label claim (mg) Conc. found (mg) Mean 6 SD %Drug found Mean% 6 SD %RSD
A 40 39.678 39.734 6 0.1304 99.33 99.37 6 0.31324 0.315
39.904 99.76
39.598 98.99
39.756 99.39
B 40 39.444 39.388 6 0.13179 98.61 98.47 6 0.32946 0.334
39.542 98.85
39.323 98.31
39.243 98.11
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The calculation was done by using the formula:
Artemether  content  (mg) 5 (Area  test/Area 
std) 3 (100/10) 3 (0.5/10) 3 (50/wt  capsule 
powder) 3 (potency of std/100) 3 (average wt powder/cap)
Forced degradation studies
Acid hydrolysis
0.5 ml of a standard stock solution (10 mg/ml) was 
transferred to a 10 ml volumetric flask and in this 1 ml of 
0.01 N HCl, volume was made to about 5 ml with mobile 
phase and heated on the water bath at 60ºC for 3 hours. 
Flask was then cooled to room temperature and diluted 
up to mark with mobile phase. Solution was then filtered 
through 0.45 mm filter, and 20 ml solution was injected 
[Figure 1].
Alkaline hydrolysis
0.5 ml of standard stock solution (10 mg/ml) was 
transferred to 10 ml volumetric flask and in this 1 ml of 
0.001 N NaOH, volume was made to about 5 ml with 
Figure 1: Chromatogram obtained after treating a 0.5 ml of the standard 
stock solution with 1 ml of 0.01 N HCl at 608C for 3 h
Figure 2: Chromatogram obtained after treating a 0.5 ml of the standard 
stock solution with 1 ml of 0.001 N NaOH at 608C for 6 h
Figure 4: Chromatogram obtained after heating drug at 608C for 24 h 
mobile phase and heated on the water bath at 60ºC for 
6 hours. Flask was then cooled to room temperature and 
diluted up to mark with mobile phase. Solution was then 
filtered through 0.45 mm filter and 20 ml solution was 
injected [Figure 2].
Oxidation
0.5 ml of the stock solution (10 mg/ml) was taken in a 
10 ml volumetric flask and 1 ml of 3% H2O2 was then 
added. The solution was then kept at room temperature 
for 18 h. The solution was then filtered through 0.45 mm 
filter, and 20 ml solution was injected [Figure 3].
Thermal degradation
Dry heat
100 mg drug was taken in a 10 ml volumetric flask and 
heated in the oven at 608C for 24 h, diluted up to the mark 
with the mobile phase. The solution was then filtered 
through 0.45 mm filter, and 20 ml solution was injected 
[Figure 4].
Figure 3: Chromatogram obtained after treating a 0.5 ml of the standard 
stock solution with 3% H2O2 kept overnight at RT for 24 hJ Young Pharm Vol 2 / No 1  83
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Figure 5: Chromatogram obtained after heating a 0.5 ml of stock 
solution diluted to about 5 ml heated on the water bath at 1008C for 4 h
Table 4: Summary of results of forced degradation studies
Sample exposure condition No. of degradation products (RT) Figure no. %Degradation (6SD) S.E.M %Recovery
Acid hydrolysis 5 (3.16, 3.42, 3.68, 3.89, 7.18) 1. a 22.312 (64.3) 0.91 77.69
Alkaline hydrolysis 5 (2.0, 2.21, 3.39, 3.69, 4.43) 1. b 15.747 (63.8) 1.6 84.25
Oxidation 3 (2.04, 3.69, 5.10) 1. c 13.622 (64.2) 0.88 86.38
Heat
Dry 5 (2.02, 2.26, 3.41, 3.93, 4.91) 1. d 11.444 (63.6) 1.2 88.56
Wet 7 (3.66, 3.87, 4.40, 4.83, 5.75, 6.13, 7.01) 1. e 12.813 (65.4) 2.4 87.18
Table 5: Summary of validation parameters
Linearity 250-750 (mg/ml); r 5 0.9998
Range (mg/ml)
Linear range 250-750
Working range 21.831-750
Target range 400, 500 and 600
Target concentration 500
Precision (%RSD)
Repeatability 0.256
Intraday 0.642
Interday 0.712
Accuracy (%recovery) 99.36
LOD (mg/ml) 7.20445
LOQ (mg/ml) 21.8317
Wet heat
0.5 ml of the standard stock solution (10 mg/ml) of drug 
was transferred to a 10 ml volumetric flask and diluted 
with about 5 ml of the mobile phase and kept on water 
bath at 1008C for 4 h. The solution was then filtered 
through 0.45 mm filter, and 20 ml solution was injected 
[Figure 5].
UV treatment
0.5 ml of the standard stock solution (10 mg/ml) was 
transferred to a 10 ml volumetric flask, diluted to the mark, 
and kept in UV chamber overnight for 24 h. The solution 
was then filtered through 0.45 mm filter, and 20 ml solution 
was injected, no degradation was observed.
CONCLUSION
The developed HPLC technique is precise, accurate, specific, 
and stability indicating. Statistical analysis proves that the 
method is repeatable and selective for the analysis of 
artemether as bulk drug and in pharmaceutical formulations. 
The summary of results of stability studies and validation 
parameters of method are presented in Tables 4 and 5 
respectively. The method can be used to determine the purity 
of the drug available from various sources by detecting 
the related impurities. It may be extended to study the 
degradation kinetics of artemether and for its estimation 
in plasma and other body fluids. As the method separates 
the drug from potential degradation products in different 
storage conditions with the resolution of more than 1.5, it 
is stability indicating.
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